SCHEMBL12640333

SCHEMBL12640333

COc1ncc(CNc2ncc(Br)cc2C)cc1F

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.46
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CHRM4 P08173 1/20 0.38
NPC1 O15118 2/20 0.38
PIK3CA P42336 10/20 0.37
PIK3R1 P27986 3/20 0.37
GAA P10253 1/20 0.37
ALOX12 P18054 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
WNT3A P56704 1/20 0.33
MTOR P42345 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12675576 0.90 CYP3A4 (0.45) CYP3A4ALDH1A1MAPTCYP2C9CYP1A2
SCHEMBL12640368 0.83 PIK3CA (0.47) CYP3A4ALDH1A1CHRM4PIK3CAPIK3R1
SCHEMBL12640332 0.80 CYP3A4 (0.45) CYP3A4ALDH1A1MAPTCYP2C9CYP1A2
SCHEMBL2599923 0.77 CYP3A4 (0.47) CYP3A4ALDH1A1MAPTCYP2C9CYP1A2
SCHEMBL12640336 0.76 ALDH1A1 (0.42) CYP3A4ALDH1A1MAPTCYP2C9CYP1A2
SCHEMBL12675577 0.75 PIK3CA (0.46) CYP3A4ALDH1A1MAPTCYP2C9CHRM4
SCHEMBL12675584 0.74 CYP3A4 (0.45) CYP3A4ALDH1A1MAPTCYP1A2CYP2D6
SCHEMBL322917 0.74 PIK3CA (0.41) CYP3A4MAPTPIK3CAPIK3R1MTOR
SCHEMBL1882060 0.74 CYP3A4 (0.79) CYP3A4CYP2C9CYP2C19
SCHEMBL12640329 0.72 MAPT (0.50) CYP3A4ALDH1A1MAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 US disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 WO disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP3A4 3717/4885ALDH1A1 2981/4885MAPT 1276/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP3A4 3717/4885ALDH1A1 2981/4885MAPT 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.